Many pharmaceutical drugs reach the large intestine where they encounter - and potentially interact with - hundreds to thousands of different microbial species. We aim to understand the impact of drugs on the composition and activity of the human gut microbiota and the repercussions this may have on the host.
In the gut, the host and microbiota are in constant communication, and small molecules such as microRNAs (miRNAs) are important for this crosstalk. We aim to better understand the role of miRNAs in gut microbiota modulation in health and disease, such as inflammatory bowel disease.
Using single-cell techniques such as fluorescence in situ hybridisation, multi-parametric microbiota flow cytometry, isotope tracing and next-generation sequencing we are mapping the activity of key gut microbes in situ, in homeostasis and under perturbation, during inflammatory disease.